The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Announce Highlights of

The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life
Foundation & STOQ International Announce Highlights of the Upcoming Second
International Adult Stem Cell Conference

Highlights Include Keynote by Nobel Prize Winner, Dr. John Gurdon

NEW YORK, March 22, 2013 (GLOBE NEWSWIRE) -- The Stem for Life Foundation,
NeoStem, Inc. (NYSE MKT:NBS), The Pontifical Council for Culture, and STOQ
International today released details on the program of The Second
International Vatican Adult Stem Cell Conference: Regenerative Medicine — A
Fundamental Shift in Science & Culture, taking place from within The Vatican,
April 11-13, 2013.

This event is part of a five-year collaboration between The Stem for Life
Foundation, a not-for-profit organization devoted to raising global awareness
of the therapeutic potential of adult stem cells, NeoStem, a leader in the
emerging cellular therapy industry, The Vatican's Pontifical Council for
Culture and its foundation, called STOQ International (Science, Theology and
the Ontological Quest).

"Regenerative medicine is poised to revolutionize disease management by
finding new ways to boost the body's ability to heal itself. Whereas today,
treatment for many diseases is a matter of managing symptoms, regenerative
medicine seeks to reverse the course of the disease by targeting its cause and
repairing diseased or defective tissues or organs," said Dr. Robin Smith,
President of The Stem for Life Foundation and CEO of NeoStem. "This conference
brings together a notable group of adult stem cell researchers, educators,
policy experts, ethicists, patients, and religious officials."

The goals of the 2013 Second International Vatican Adult Stem Cell Conference
are to:

  *Foster an open dialogue amongst researchers, physicians, philanthropists,
    faith leaders and policy-makers in order to help identify clear, unmet
    medical needs throughout the world that can be addressed through the
    development of cellular therapies that will reduce human suffering.
    
  *Expand global awareness of the here-and-now opportunities of adult stem
    cell therapies, reducing misperceptions surrounding the field of cellular
    research.
    
  *Lay the groundwork for a collaborative network of scientists, educators
    and patrons who embrace the promise of adult stem cells, creating an array
    of subsequent educational events at leading universities and institutions
    throughout the world, inspiring the next generation of cellular
    researchers.

The conference will be moderated by Meredith Vieira from NBC News, Bill Hemmer
from The Fox News Channel, and Dr. Max Gomez from WCBS-TV.Highlights of the
conference will include:

  *Hope for the future of adult stem cell therapy for multiple sclerosis
    ("MS"), featuring Richard M. Cohen, journalist and husband of Ms. Vieira,
    Dr. Richard Burt of Northwestern University, Dr. Saud Sadiq of the MS
    Research Center of New York, and multiple sclerosis patients who
    participated in clinical trials and have been successfully treated with
    adult stem cells.We will also take a look atTcelna™, Opexa Therapeutics
    (Nasdaq:OPXA) T-cell immunotherapy in development for secondary
    progressive multiple sclerosis.
    
  *Keynote speech by Dr. John Gurdon, 2012 Nobel Prize Winner for Physiology
    or Medicine for his work on transforming adult cells into stem cells.
    
  *Overview of contemporary stem cell transplants and current research for
    thetreatmentof cancer and osteogenesis imperfecta with field experts,
    featuring Dr. Edwin Horwitz of Children's Hospital of Philadelphia
    (UPENN), Dr. Stephen Nimer of the Sylvester Comprehensive Cancer Center,
    and Dr. Amitabha Mazumder of the NYU Clinical Cancer Center.
    
  *An in-depth look at many of the companies, such as NeoStem, Athersys
    (Nasdaq:ATHX), and Mesoblast (ASX:MSB) (USOTC:MBLTY), making progress in
    developing adult stem cell therapies for cardiovascular disease.
    
  *A dynamic panel on the politics, perceptions and promise of cell
    therapies, moderated by Peggy Noonan of The Wall Street Journal and
    featuring former U.S. Health and Human Services Secretary and Governor,
    Tommy G. Thompson, former U.S. Senator, Norm Coleman, former member of the
    President's Council on Bioethics, William Hurlbut, and University College
    London Professor of Regenerative Medicine Bioprocessing, Chris Mason.
    
  *Sessions on developments in cellular therapies for organ and tissue repair
    anddiabetes, as well as on the potential to use stem cells to treat
    traumatic brain injury and other neurodegenerative diseases. We will
    discuss differences among adult stem cells and learn about exciting work
    on the potential to use placental stem cells to treat autoimmune diseases.
    
  *We will hear from Dr. Robert Preti, President and Chief Scientific Officer
    of Progenitor Cell Therapy (PCT), on how to turn an adult stem cell into a
    therapy.
    
  *The story of Osiris Therapeutics' (Nasdaq:OSIR) successful approval of an
    adult stem cell therapy in Canada and elsewhere for graft-vs-host disease,
    Prochymal®, with Osiris CEO, Dr. C. Randal Mills.
    
  *There will also be discussion about education, faith, and science with
    respect to a future with cellular therapy by Dr. Phillip Sloan (University
    of Notre Dame) and Rev. Nicanor Pier Giorgio Austriaco, O.P. (Providence
    College), as well as discussion around the social and cultural
    considerations by Dr. Malik Hasan, Founder of Qual-Med, consideration of
    the moral and ethical implications of adult stem cell research, and
    consideration of how to prepare the future generation of leaders and
    scholars by Dr. Anthony J. Cernera, President of the Center for
    Interreligious Understanding.
    
  *Panel discussions will look at the new frontiers of cellular research
    pertaining to stem cells, health, longevity and epigenetics. We will
    examine the ties between stem cell health and aging and hear from experts
    in the field, including Dr. Vincent Giampapa (University of Medicine and
    Dentistry, New Jersey), Dr. Ronald DePinho (University of Texas MD
    Anderson Cancer Center), Dr. Wayne A. Marasco (Dana-Farber Cancer
    Institute), and Dr. Mariusz Z. Ratajczak (University of Louisville). Dr.
    Valter Longo (University of Southern California, Davis), Dr. Jaime
    Guevara-Aguirre (Institute of Endocrinology, Quito, Ecuador), and Dr. Nir
    Barzilai (Albert Einstein College of Medicine) will look at fascinating
    case studies on longevity and disease resistance, including a unique look
    at 'Laron dwarfs' and their absence of cancer and chronic disease.

Some corporate sponsors of the conference include NeoStem, Mesoblast, Celgene
(Nasdaq:CELG), Opexa Therapeutics, Lowenstein Sandler, Aspire Capital
Partners, Kenyon & Kenyon, and the Maxim Group. Major support also comes from
philanthropists who believe in the promise of adult stem cells. To learn more
about The Second International Vatican Adult Stem Cell Conference please visit
www.adultstemcellconference.org.

About The Pontifical Council for Culture

The Pontifical Council for Culture is that Dicastery of the Roman Curia which
assists the Pope in the exercise of his supreme pastoral office for the
benefit and service of the universal Church and of particular Churches
concerning the encounter between the saving message of the Gospel and
cultures, in the study of the weighty phenomena of the rift between the Gospel
and cultures; indifference in matters of religion; unbelief. It is also
concerned with relationships between the Church and the Holy See and the world
of culture; in particular it promotes dialogue with contemporary cultures, so
that human civilization may become increasingly open to the Gospel, and so
that men and women of science, letters and the arts may know that the Church
acknowledges their work as a service to truth, goodness and beauty.
www.cultura.va

About STOQ International

STOQ International is a non-profit 501(c)3 tax-exempt organization operating
in the U.S. for the purpose of creating important dialogue between the Church
and contemporary culture, which is strongly shaped by scientific advancements.

Its aim is to change the debate in the arena of ideas related to Theology,
Philosophy and present-day Science, through supporting and encouraging
scientific research, educational programs and cultural initiatives. The
alliance of experts from the disciplines of science, theology and philosophy
that form the STOQ Project provokes a renewal of thinking about God and man,
creation and providence. STOQ International wants thus to challenge the public
perception of the relationship between the Church tradition and science, and
we prove the compatibility of faith and reason in the pursuit of knowledge.

The purpose of STOQ is to endorse and conduct an interdisciplinary dialogue in
order to build a culture that promotes the full dignity of humanity. The main
mission of STOQ is to build a bridge between science and theology, providing
for their positive impact on contemporary society, as well as to support
studies through joint research projects, conferences and educational &
cultural enterprises.

To know more about STOQ, please visit: www.stoqinternational.com

About The Stem for Life Foundation

The Stem for Life Foundation (SFLF) is dedicated to improving the quality of
life of millions of people suffering from dozens of painful and sometimes
debilitating medical conditions by providing information and updates about
adult stem cell research, therapy development and possible healthcare
applications. SFLF focuses on educating the public, convening the best minds
in adult stem cell medicine and research, supporting clinical research, and
subsidizing adult stem cell collection and storage for those who need it most.

Understanding that adult stem cell research could lead to better treatments
and possibly cures for chronic disease, as well as reduce health care costs
and improve quality of life for those with chronic disease and disability,
SFLF was established in 2007. SFLF's Board of Trustees and staff are deeply
committed to expediting development of stem cell therapies that offer real
hope to individuals suffering from a wide-range of life-threatening medical
conditions.

For more information on the Stem for Life Foundation, please visit
http://www.stemforlife.org

About NeoStem, Inc.

NeoStem, Inc. (the "Company") is a leader in the emerging cellular therapy
industry. Our business model includes the development of novel proprietary
cell therapy products as well as operating a contract development and
manufacturing organization ("CDMO") providing services to others in the
regenerative medicine industry. The combination of a therapeutic development
business and revenue-generating service provider business provides the Company
with capabilities for cost effective in-house product development and
immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the successful execution
of the Company's business strategy, including with respect to the Company's or
its partners' successful development of AMR-001 and other cell therapeutics,
the size of the market for such products, its competitive position in such
markets, the Company's ability to successfully penetrate such markets and the
market for its contract development and manufacturing business, and the
efficacy of protection from its patent portfolio, as well as the future of the
cell therapeutics industry in general, including the rate at which such
industry may grow. The Company's actual results could differ materially from
those anticipated in these forward- looking statements as a result of various
factors, including but not limited to matters described under the "Risk
Factors" in the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 11, 2013 and in the Company's other periodic
filings with the Securities and Exchange Commission, all of which are
available on its website. The Company does not undertake to update its
forward-looking statements. The Company's further development is highly
dependent on future medical and research developments and market acceptance,
which is outside its control.

CONTACT: Todd Aydelotte, Managing Director
         Allison+Partners
         Phone: +1-646-428-0644
         Email: todd@allisonpr.com
 
Press spacebar to pause and continue. Press esc to stop.